Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC
Population-based assessment of the association between socioeconomic deprivation and utilization of novel therapies in patients with NSCLC from the United Kingdom, presented at WCLC 2022 and reported by Clinical Care Options (CCO)
Prespecified interim analysis of OS from phase III IMpower010 trial of adjuvant atezolizumab in early-stage NSCLC, presented at WCLC 2022 and reported by Clinical Care Options (CCO)
Cohort from phase Ib CodeBreaK100/101 studies of sotorasib + atezolizumab or pembrolizumab in KRAS G12C-mutated NSCLC, presented at WCLC 2022 as reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.